You are here

P&T April 2018


Health Systems Take Matters Into Their Own Hands

Generic shortages are draining hospital resources throughout the U.S. and in some cases imperiling inpatient treatment. The author considers the FDA’s performance and describes the approach some health systems are taking to create a solution.

Staying up to date with evolving pharmacotherapies is important to providing optimal therapies to patients. The authors present available evidence to support the role of novel and existing agents in treating type-2 diabetes.

The authors briefly review febrile neutropenia, describe risk assessment tools, and discuss treatment and prophylactic options for this serious complication.

Pipeline Plus

Despite failures in late-phase trials, the pipeline of medications for Alzheimer’s disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.

We present coverage of advances in renal cell carcinoma and prostate cancer.


Medication Errors

Harm and death associated with methotrexate errors

Prescription: Washington

CMS consideration of rebate overhaul elicits strong opinions

Approvals, new indications, regulatory activities, and more

Netarsudil ophthalmic solution (Rhopressa) for the reduction of elevated intraocular pressure; ertugliflozin (Steglatro) for adults with type-2 diabetes; and lutetium lu 177 dotatate (Lutathera) for certain gastroenteropancreatic neuroendocrine tumors

Drug Forecast

Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation